Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN II 20 versus LIQREV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN II 20 versus LIQREV.
LIPOSYN II 20% vs LIQREV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lipid emulsion providing essential fatty acids (linoleic and linolenic acids) and calories for parenteral nutrition. The triglycerides are hydrolyzed by lipoprotein lipase to free fatty acids and glycerol, which are then utilized for energy or stored.
Liqrev (sildenafil) is a phosphodiesterase-5 (PDE5) inhibitor. It enhances the effect of nitric oxide by inhibiting PDE5, which degrades cGMP in the corpus cavernosum, leading to increased cGMP levels and smooth muscle relaxation, thereby facilitating penile erection.
Intravenous fat emulsion; 20% formulation: Initial rate 1 mL/min for 15-30 minutes, then increase to 2 mL/min if tolerated. Max infusion rate: 100 mL/hour. Total daily dose: 1-2 g/kg (5-10 mL/kg) to provide up to 60% of nonprotein calories.
LIQREV (ivermectin) 200 mcg/kg orally once, taken on an empty stomach with water.
None Documented
None Documented
Terminal elimination half-life of triglycerides is approximately 30 minutes for the fast phase and 12-24 hours for the slow phase, reflecting clearance from plasma and tissue distribution.
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min).
Intravenous lipid emulsions are metabolized by lipoprotein lipase and eliminated as free fatty acids; less than 1% excreted unchanged in urine, negligible biliary/fecal excretion.
Primarily renal (70% as unchanged drug, 15% as glucuronide conjugate); 10% biliary/fecal.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion